摘要
目的探讨脑梗死急性期患者以丁苯酞联合尤瑞克林治疗对认知功能、血管内皮功能以及氧化应激水平的影响。方法48例脑梗死急性期患者,采用随机数字表法将其分为对照组和观察组,各24例。所有患者入院后均进行常规治疗,对照组在此基础上加用注射用尤瑞克林,观察组在对照组基础上加用丁苯酞软胶囊。比较两组临床疗效、认知功能、血管内皮功能及氧化应激水平。结果治疗后,观察组患者的临床总有效率91.67%高于对照组的66.67%(P<0.05)。治疗后,两组蒙特利尔认知评估量表(MoCA)各项评分均明显高于治疗前,且观察组定向力、选项、抽象能力、视空间功能、命名、注意力、语言评分分别为(4.94±0.48)、(5.04±0.47)、(1.90±0.48)、(4.67±1.05)、(2.76±0.76)、(5.13±0.95)、(2.66±0.86)分,高于对照组的(3.51±0.32)、(3.89±0.28)、(0.95±0.28)、(3.42±0.48)、(1.90±0.47)、(4.27±0.66)、(1.93±0.47)分(P<0.05)。治疗后,两组血清内皮素-1(ET-1)、一氧化氮(NO)、一氧化氮合酶(NOS)、血管内皮生长因子(VEGF)水平均较治疗前降低,且观察组ET-1(77.26±10.96)ng/L、NO(33.81±5.63)μmol/L、NOS(13.59±4.53)μmol/L、VEGF(212.96±24.45)ng/L低于对照组的(107.71±11.58)ng/L、(49.74±8.99)μmol/L、(26.32±6.33)μmol/L、(278.87±28.94)ng/L,统计学差异显著(P<0.05)。两组治疗后血清基质金属蛋白酶-9(MMP-9)、丙二醛(MDA)水平均较治疗前降低,观察组MMP-9(122.72±26.04)U/ml、MDA(3.08±0.44)μmol/L低于对照组的(161.63±28.66)U/ml、(4.14±0.97)μmol/L;血清总抗氧化力(T-AOC)、超氧化物歧化酶(SOD)水平均较治疗前升高,观察组T-AOC(12.10±0.61)U/ml、SOD(96.17±13.35)U/ml高于对照组的(10.52±0.67)、(80.53±28.97)U/ml,统计学差异显著(P<0.05)。结论脑梗死急性期患者以丁苯酞联合尤瑞克林治疗能够提高临床疗效,改善认知功能,减轻血管内皮损伤,改善氧化应激反应。
ion,visuospatial function,naming,attention and language in the observation group were(4.94±0.48),(5.04±0.47),(1.90±0.48),(4.67±1.05),(2.76±0.76),(5.13±0.95)and(2.66±0.86)points,which were higher than(3.51±0.32),(3.89±0.28),(0.95±0.28),(3.42±0.48),(1.90±0.47),(4.27±0.66)and(1.93±0.47)points in the control group(P<0.05).After treatment,the serum levels of endothelin-1(ET-1),nitric oxide(NO),nitric oxide synthase(NOS)and vascular endothelial growth factor(VEGF)in both groups were lower than those before treatment;the observation group had ET-1 of(77.26±10.96)ng/L,NO of(33.81±5.63)μmol/L,NOS of(13.59±4.53)μmol/L,VEGF of(212.96±24.45)ng/L,which were lower than(107.71±11.58)ng/L,(49.74±8.99)μmol/L,(26.32±6.33)μmol/L,(278.87±28.94)ng/L in the control group;the difference was statistically significant(P<0.05).After treatment,the serum levels of matrix metalloproteinase-9(MMP-9)and malondialdehyde(MDA)in both groups were lower than those before treatment,and the serum levels of total antioxidant capacity(T-AOC)and superoxide dismutase(SOD)were higher than those before treatment;MMP-9 of(122.72±26.04)U/ml and MDA of(3.08±0.44)μmol/L in the observation group were lower than(161.63±28.66)U/ml and(4.14±0.97)μmol/L in the control group;T-AOC of(12.10±0.61)U/ml and SOD of(96.17±13.35)U/ml in the observation group were higher than(10.52±0.67)and(80.53±28.97)U/ml in the control group;the difference was statistically significant(P<0.05).Conclusion In patients with acute phase of cerebral infarction,butylphthalide combined with urinary kallidinogenase can improve clinical efficacy,cognitive function,reduce vascular endothelial injury and improve oxidative stress response.
作者
许荥洁
黄彬舟
XU Ying-jie;HUANG Bin-zhou(Department of Neurology,the Third People's Hospital of Zhangjiagang,Suzhou 215600,China)
出处
《中国实用医药》
2024年第4期11-14,共4页
China Practical Medicine
关键词
脑梗死
急性期
尤瑞克林
丁苯酞
认知功能
血管内皮功能
氧化应激
Cerebral infarction
Acute phase
Urinary kallidinogenase
Butylphthalide
Cognitive function
Vascular endothelial function
Oxidative stress
